SCHEMBL710686

SCHEMBL710686

CCOC(=O)c1cnc2[nH]c(-c3cc(OCc4ccccc4)cc(OCc4ccccc4)c3)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HSP90AA1 P07900 1/20 0.47
GABRA1 P14867 3/20 0.46
GABRG2 P18507 3/20 0.46
GABRB3 P28472 3/20 0.46
GABRA5 P31644 3/20 0.46
GABRA3 P34903 3/20 0.46
GABRA2 P47869 3/20 0.46
CHEK2 O96017 1/20 0.45
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
PRMT5 O14744 3/20 0.44
NMT1 P30419 3/20 0.43
NMT2 O60551 1/20 0.43
ALDH1A1 P00352 2/20 0.42
GABRP O00591 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709520 0.94 GCK (0.49) MAOBMEN1KMT2AHSP90AA1GABRA1
SCHEMBL2668214 0.88 CHEK2 (0.48) MAOBMEN1KMT2ACHEK2PRMT5
SCHEMBL712755 0.88 MEN1 (0.53) MEN1KMT2ACHEK2ALDH1A1HPGD
SCHEMBL10206496 0.85 MAOB (0.51) MAOBMEN1KMT2AHSP90AA1GABRA1
SCHEMBL712331 0.83 GCK (0.57) MEN1KMT2ACHEK2
SCHEMBL2668328 0.82 CHEK2 (0.41) MEN1KMT2ACHEK2PRMT5MAPT
SCHEMBL711135 0.82 PKN1 (0.42) MAOBMEN1KMT2AGABRA1GABRG2
SCHEMBL10206497 0.81 MAOB (0.47) MAOBMEN1KMT2AHSP90AA1GABRA1
SCHEMBL710541 0.81 MAOB (0.47) MAOBMEN1KMT2AHSP90AA1GABRA1
Trifluoroacetic Acid SCHEMBL710612 0.81 MAOB (0.49) MAOBMEN1KMT2AHSP90AA1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK MAOB 1046/4885MEN1 2868/4885KMT2A 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.